u/hub_ops

Interval stretching changes the exposure profile: with a week-long half-life, moving to ten or twelve days lowers trough concentration more than it lowers average exposure. That is why appetite return is often the first thing noticed.

The lyophilised cake displaces a small volume, so the true concentration is very slightly lower than the arithmetic suggests. It is a fraction of a percent and it is dwarfed by fill tolerance.

Left up and flaired Proposal — it has replacement wording, which is what this board asks for.

I would not treat a two-kilo range as drift requiring action.

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

glucagon agonism and energy expenditure is the mechanistic thread

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

if the maths gives you a fraction of a unit, change the concentration

the nausea profile is genuinely gentler than people expect coming from sema

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

The two levers, described properly, because this board mixes them up constantly.

Reducing the dose lowers average exposure while keeping the weekly rhythm. Stretching the interval keeps the dose but lowers the trough between injections, which — with a week-long half-life — is why people notice appetite returning towards the end of a stretched cycle before they see anything on the scale.

The reported pattern here is stretching in small steps, a week to ten days to twelve, with appetite as the signal rather than the scale. Some people find dose reduction more comfortable. Neither is a schedule anybody here can hand you, and the fact that this phase has the least published guidance is exactly why board consensus deserves less weight than usual.

maintenance is where the logistics finally get boring, which is the point

The failure modes I have actually seen posted here, in order of frequency.

One: reconstituting at a different volume than intended and not writing it down, so the next draw is based on a remembered concentration. Two: treating units as a dose rather than a volume, which breaks the moment the concentration changes. Three: assuming a syringe is U-100 when it is not.

All three are solved by the same two habits — do the arithmetic before the water goes in, and write the result on the glass. Neither costs anything and between them they cover almost every question this board gets.

do not chase the last two kilos with a dose increase

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

The honest evidence position, written out so this board does not drift.

Phase 2 data exists in a specific, biopsy-characterised population, with a slow protocol escalation and tolerability tables worth reading in full. Nothing containing this compound is approved by any regulator anywhere. Research-use-only material is not approved for human use.

Independent purity results across this entire site number in the low single figures. That means nobody here — including the people who post most confidently — has a basis for statements about batch-to-batch consistency. If you test something, post it; the log is the only thing that will change that position.

6kg over 21 weeks, never went past 10mg, and fatigue stayed mild the whole way. Posting because the loud threads are all 15mg.

Aim the stream down the wall of the vial rather than into the cake. Reconstitution is a solubility problem, not a mixing problem, and mechanical shear does nothing helpful.

nausea profile in the combination trials is the thing to read carefully

Push back: that is not a plateau, that is maintenance. You have arrived and you are describing it as a failure.

Which trial, and which arm?

niels_norgaard is right about the programme names. They are different populations with different endpoints.

write the concentration on the vial in marker, that is the whole post

Drifted up 17kg over a winter and panicked. It came back off without any change, which is apparently just what weight does.

Correction: that trial measured regain after withdrawal, not failure of the drug during treatment. Very different claim.

Moderation of individual cases happens in modmail rather than in threads, because a public discussion of one person’s removal is worse for that person than a private one.

stepping every four weeks is a ceiling on speed, not a schedule you must hit

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

No escalation schedules for other members, on any compound, and especially not an unapproved one.

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

read the endpoint before you read the headline

Reminder that nobody in this thread is your clinician and the sidebar says so for a reason.

Adopted with an amendment, announced with the reasoning. Thank you for writing actual text.

Complained about a rule without proposing anything and was politely pointed at this page. Fair.

Had a post removed, went to modmail, got a specific explanation and disagreed with it politely. It stayed removed and I understood why.

Proposed a rule change here with actual wording and it was adopted. That is the process working and it is not fast.

The dead space question sent me down a rabbit hole for a week. It is a fraction of a unit and it is the same every draw.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.